Exploring the Anticancer Potential of Origanum majorana Essential Oil Monoterpenes Alone and in Combination against Non-Small Cell Lung Cancer

被引:6
|
作者
Arafat, Kholoud [1 ]
Al-Azawi, Aya Mudhafar [1 ]
Sulaiman, Shahrazad [1 ]
Attoub, Samir [1 ,2 ]
机构
[1] United Arab Emirates Univ, Dept Pharmacol & Therapeut, Coll Med & Hlth Sci, Al Ain 15551, U Arab Emirates
[2] United Arab Emirates Univ, ASPIRE Precis Med Res Inst Abu Dhabi, Al Ain 15551, U Arab Emirates
关键词
NSCLC; monoterpenes; terpinen-4-ol; sabinene hydrate; alpha-terpinene; gamma terpinene; survivin; tumor growth; IN-VITRO; CYTOTOXICITY; ANTIOXIDANT;
D O I
10.3390/nu15235010
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Lung cancer is the second most commonly diagnosed cancer and has the highest mortality rate worldwide despite the remarkable advances in its treatment. Origanum majorana Essential Oil (OMEO) has been shown to be effective against non-small cell lung cancer (NSCLC) cells, decreasing their viability and colony growth in vitro, as well as inhibiting tumor growth in chick embryo chorioallantoic membranes (CAM) and nude mice in vivo. OMEO is mainly composed of four monoterpenes, namely terpinen-4-ol, sabinene hydrate, alpha-terpinene, and gamma-terpinene. In this study, we aimed to investigate the potential anticancer effects of these monoterpenes, either alone or in combination, on NSCLC. Our findings indicate that these four monoterpenes significantly decreased NSCLC cell viability in a concentration-dependent manner, reduced their colony growth in vitro, and also downregulated survivin expression in these cells. Moreover, different combined mixtures of these monoterpenes further enhanced their anticancer effects on cellular viability, with a terpinen-4-ol and sabinene hydrate combination being the most potent. We also found that terpinen-4-ol, in combination with sabinene hydrate, markedly enhanced the anticancer effect of the individual monoterpenes on NSCLC viability within a shorter treatment duration through, at least in part, survivin downregulation. Furthermore, this combination enhanced the inhibition of colony growth in vitro and the tumor growth of NSCLC cells xenografted onto chick embryo CAM in vivo. Altogether, our study highlights the potential of these monoterpenes for use in further pre-clinical investigations against various cancer hallmarks.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer
    Fu, Bingjie
    Dou, Xiaojing
    Zou, Miao
    Lu, Hao
    Wang, Kaixuan
    Liu, Qingxia
    Liu, Yao
    Wang, Wei
    Jin, Meihua
    Kong, Dexin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC)
    Desai, Aakash
    Subbiah, Vivek
    Dimou, Anastasios
    Deshane, Jessy
    Goliwas, Kayla
    Ponnazhagan, Selvarangan
    Das, Devika Govind
    Khalil, Maya
    Lo, Ying-Chun
    Lin, Edwin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer
    Adjei, AA
    Argiris, A
    Murren, JR
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 32 - 40
  • [4] Therapeutic potential of YM155 alone and in combination with chemotherapeutics against human non-small cell lung cancer in carcinoma xenograft models
    Yamanaka, K.
    Nakahara, T.
    Kita, A.
    Miyoshi, S.
    Noda, A.
    Takeuchi, M.
    Kinoyama, I.
    Koutoku, H.
    Nishimura, S.
    Sasamata, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 112 - 112
  • [5] Combination Immunotherapy in Non-small Cell Lung Cancer
    Melina E. Marmarelis
    Charu Aggarwal
    Current Oncology Reports, 2018, 20
  • [6] Combination Immunotherapy in Non-small Cell Lung Cancer
    Marmarelis, Melina E.
    Aggarwal, Charu
    CURRENT ONCOLOGY REPORTS, 2018, 20 (07)
  • [7] Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer
    Liu, Ke-jun
    Ding, Ling-yu
    Wu, Hai-ying
    TUMOR BIOLOGY, 2015, 36 (03) : 1323 - 1327
  • [8] Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer - Discussion I
    Fossella, FV
    Green, MR
    Eckardt, JR
    Wozniak, AJ
    Socinski, MA
    Murren, JR
    SEMINARS IN ONCOLOGY, 1999, 26 (05) : 41 - 42
  • [9] Immunotherapy for non-small cell lung cancer (NSCLC), as a stand-alone and in combination therapy
    Kaur, Jasmine
    Elms, Jackson
    Munn, Alan L.
    Good, David
    Wei, Ming Q.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 164
  • [10] Anticancer treatment for advanced non-small cell lung cancer
    Sculier, J-P.
    BREATHE, 2011, 8 (02) : 124 - 133